

JEREMIAH B. FRUEAUF
ASSOCIATE
(202) 772-8506
JFRUEAUF@SKGF.COM



February 1, 2012

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Confirmation No. 2306
Art Unit 1646
Attn: Mail Stop Amendment

Re: U.S. Utility Patent Application
Appl. No. 10/587,714; § 371(c) Date: June 4, 2007
For: **Treatment of Conditions Involving Dopaminergic Neuronal
Degeneration Using Nogo Receptor Antagonists**
Inventor: RELTON *et al.*
Our Ref: 2681.0450001/EJH/JBF

Sir:

Transmitted herewith for appropriate action is the following document:

1. Statement of Substance of Interview In Accordance With 37 C.F.R. § 1.133(b) and M.P.E.P. § 713.04.

The above-listed document is filed electronically through EFS-Web.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Jeremiah B. Frueauf
Attorney for Applicants
Registration No. 66,638

JBf/rjv
Enclosures

1478539_1.DOCX